

Seres Therapeutics to Present at Jefferies Microbiome-Based Therapeutics Summit

April 15, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 15, 2021-- <u>Seres Therapeutics, Inc</u>. (Nasdaq: MCRB) a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday, April 22, 2021.

The pre-recorded presentation will be made available under the "Investors and Media" section of Seres' website on Thursday, April 22, 2021 at 8:00 a.m. ET and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent *C. difficile* infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres' SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit <u>www.serestherapeutics.com</u>.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005172/en/

PR Contact Kristin Ainsworth kainsworth@serestherapeutics.com

IR Contact Carlo Tanzi, Ph.D. ctanzi@serestherapeutics.com

Source: Seres Therapeutics, Inc.